N-(1,5-dimethyl-3-oxo-2-phenylpyrazol-4-yl)-3-methyl-1-phenylthieno[2,3-c]pyrazole-5-carboxamide

Request For Quotation
N-(1,5-dimethyl-3-oxo-2-phenylpyrazol-4-yl)-3-methyl-1-phenylthieno[2,3-c]pyrazole-5-carboxamide Suppliers list
Company Name: BOC Sciences  
Tel: 1-631-485-4226; 16314854226
Email: info@bocsci.com
Company Name: Shanghai YuanYe Biotechnology Co., Ltd.  
Tel: 15026964105
Email: 2881489226@qq.com
Company Name: Shanghai Rechem science Co., Ltd.  
Tel: 021-31433387 15618786686
Email: sales@rechemscience.com
Company Name: MQ (shanghai) Pharmaceuticals Co., Ltd.  
Tel: 13761635123
Email: sales@linyuepharm.com
Company Name: Shanghai Han-Xiang Chemical Co., Ltd.  
Tel: 17754423994
Email: candy@biochempartner.com
N-(1,5-dimethyl-3-oxo-2-phenylpyrazol-4-yl)-3-methyl-1-phenylthieno[2,3-c]pyrazole-5-carboxamide Basic information
Product Name:N-(1,5-dimethyl-3-oxo-2-phenylpyrazol-4-yl)-3-methyl-1-phenylthieno[2,3-c]pyrazole-5-carboxamide
Synonyms:N-(1,5-dimethyl-3-oxo-2-phenylpyrazol-4-yl)-3-methyl-1-phenylthieno[2,3-c]pyrazole-5-carboxamide;1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)-3-methyl-1-phenyl-;N-(1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)-3-methyl-1-phenyl-1H-thieno[2,3-c]pyrazole-5-carboxamide;OPA1,Inhibitor,MYLS22,optic,atrophy,endothelial,MYLS-22,inhibit,MYLS 22,tumor;MYLS22, 10 mM in DMSO;MYLS22 ，S9885;MYLS22
CAS:306959-01-3
MF:C24H21N5O2S
MW:443.52
EINECS:
Product Categories:
Mol File:306959-01-3.mol
N-(1,5-dimethyl-3-oxo-2-phenylpyrazol-4-yl)-3-methyl-1-phenylthieno[2,3-c]pyrazole-5-carboxamide Structure
N-(1,5-dimethyl-3-oxo-2-phenylpyrazol-4-yl)-3-methyl-1-phenylthieno[2,3-c]pyrazole-5-carboxamide Chemical Properties
storage temp. Store at -20°C
solubility DMSO: 83.33 mg/mL (187.88 mM)
form Solid
color Off-white to yellow
Safety Information
MSDS Information
N-(1,5-dimethyl-3-oxo-2-phenylpyrazol-4-yl)-3-methyl-1-phenylthieno[2,3-c]pyrazole-5-carboxamide Usage And Synthesis
Biological ActivityMYLS22 is a first-in-class, selective optic atrophy 1 (OPA1) inhibitor. It can target endothelial cell OPA1 to reduce tumor growth and inhibit angiogenesis by affecting NFkB activity and angiogenic gene expression.
in vivo

MYLS22 (10 mg/kg/die; peritumoral injection; every 2 days for 14 days) causes the tumor growth curtailed mice.

Animal Model: 6-week-old C57BL6/J mice with B16F10 melanomas
Dosage: 10 mg/kg/die
Administration: Peritumoral injection; every 2 days for 14 days
Result: Caused the tumor growth curtailed.
target

OPA1

N-(1,5-dimethyl-3-oxo-2-phenylpyrazol-4-yl)-3-methyl-1-phenylthieno[2,3-c]pyrazole-5-carboxamide Preparation Products And Raw materials
Tag:N-(1,5-dimethyl-3-oxo-2-phenylpyrazol-4-yl)-3-methyl-1-phenylthieno[2,3-c]pyrazole-5-carboxamide(306959-01-3) Related Product Information
N-(1,5-dimethyl-3-oxo-2-phenylpyrazol-4-yl)-3-methyl-1-phenylthieno[2,3-c]pyrazole-5-carboxamide